Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364819 · ClinicalTrials.gov registry record · Phase 1
Initial Study of Rituximab to Treat Primary Biliary Cirrhosis
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00364819 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 6 participants.
The verdict
NCT00364819, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of the anti-CD20 antibody rituximab in treating patients with Primary Biliary Cirrhosis (PBC). Rituximab is a laboratory-made antibody currently used to treat some kinds of lymphoma. Rituximab may also help people with PBC, a disease of the immune system. However, the safety of rituximab in PBC patients must first be established.
Interventions
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00364819
The ClinicalTrials.gov registry entry for NCT00364819 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT00364819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00364819 about?
NCT00364819 is a clinical study titled "Initial Study of Rituximab to Treat Primary Biliary Cirrhosis". The purpose of this study is to determine the safety of the anti-CD20 antibody rituximab in treating patients with Primary Biliary Cirrhosis (PBC). Rituximab is a laboratory-made antibody currently used to treat some kinds of lymphoma. Rituximab may also help people with PBC, a disease of the immune...
What is the current status of trial NCT00364819?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-01. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00364819?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT00364819?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.